Presented at the ASCO GU Annual Symposium (February 13–15, 2025), San Francisco
The EV-302 (KEYNOTE-A39) trial provided new insights into enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Key Findings:
Progression-Free Survival (PFS): EV+P nearly doubled median PFS compared to chemotherapy (12.5 vs. 6.3 months).
Overall Survival (OS): EV+P extended median OS from 16.1 months to 31.5 months.
Durable Responses: A 74% probability of remaining in complete response at 24 months.
Subgroup Benefit: Both cisplatin-eligible and -ineligible patients benefited from EV+P.
Safety Profile: Consistent with prior reports, no new safety concerns emerged.
These results reinforce EV+P as the new standard of care (SOC) for first-line la/mUC treatment.
A special thanks to Professor Tom Powles and all the researchers for their contributions.
For more details:https://lnkd.in/ezthg67k
